Down -12.92% in 4 Weeks, Here's Why Goodyear (GT) Looks Ripe for a Turnaround
https://www.zacks.com/stock/news/2226116/down-12-92-in-4-weeks-here-s-why-goodyear-gt-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2226116
Feb 14, 2024 - The heavy selling pressure might have exhausted for Goodyear (GT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
0
Goodyear (GT) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2225116/goodyear-gt-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2225116
Feb 12, 2024 - The headline numbers for Goodyear (GT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Auto Roundup: GT's Slew of Updates and F's Recall Draw Attention
https://www.zacks.com/stock/news/2210102/auto-roundup-gt-s-slew-of-updates-and-f-s-recall-draw-attention?cid=CS-ZC-FT-analyst_blog|stock_roundup-2210102
Jan 15, 2024 - While Goodyear (GT) makes the most noise with its partnership with TDK Corp. along with several other updates, Ford (F) grabs headlines as it recalls 140,000 vehicles.
0
Here's Why Goodyear (GT) Makes for a Solid Investment Choice
https://www.zacks.com/stock/news/2196376/here-s-why-goodyear-gt-makes-for-a-solid-investment-choice?cid=CS-ZC-FT-analyst_blog|rank_focused-2196376
Dec 11, 2023 - Goodyear's (GT) Cooper Tire buyout, forward transformation plan, strategic EMEA restructuring and leadership position in electric mobility are major tailwinds.
0
GT Biopharma submits IND to FDA for CD33+ leukemia therapy
https://seekingalpha.com/news/4042938-gt-biopharma-submits-ind-to-fda-for-cd33-leukemia-therapy?source=feed_sector_healthcare
Dec 04, 2023 - GT Biopharma (GTBP) has submitted an Investigational New Drug application to the FDA for GTB-3650 in the treatment of CD33+ leukemia, including AML and MDS. Read more here.
0
Pages: 1
Page 1